Michael Maker
Novartis
6 Papers
1 Citations
Michael Maker is an academic researcher from Novartis. The author has contributed to research in topics: Retinal & Promoter. The author has an hindex of 4, co-authored 6 publications. Previous affiliations of Michael Maker include Harvard University.
Chat about Author
Papers
Long-acting protein drugs for the treatment of ocular diseases.
Joy Ghosh,Andrew Anh Nguyen,Chad E Bigelow,Stephen Poor,Yubin Qiu,Nalini Rangaswamy,Richard Ornberg,Brittany Jackson,Howard H. Mak,Tucker Ezell,Vania Kenanova,Elisa de la Cruz,Ana Carrion,Bijan Etemad-Gilbertson,Roxana Garcia Caro,Kan Zhu,Vinney George,Jirong Bai,Radhika Sharma-Nahar,Siyuan Shen,Yiqin Wang,Kulandayan K. Subramanian,Elizabeth Fassbender,Michael Maker,Shawn Hanks,Joanna Vrouvlianis,Barrett Leehy,Debby Long,Melissa Prentiss,Viral Kansara,Bruce D Jaffee,Thaddeus P. Dryja,Michael Roguska +32 more
TL;DR: A 97-amino-acid peptide of human origin that binds hyaluronan, a major macromolecular component of the eye's vitreous, with therapeutic antibodies and proteins is combined to extend the intravitreal half-life of protein drugs as an alternative to either encapsulation or chemical modifications with polymers.
Amount of Mononuclear Phagocyte Infiltrate Does Not Predict Area of Experimental Choroidal Neovascularization (CNV)
Adrian Will-Orrego,Yubin Qiu,Elizabeth Fassbender,Siyuan Shen,Jorge Aranda,Namrata Kotagiri,Michael Maker,Sha-Mei Liao,Bruce D Jaffee,Stephen Poor +9 more
TL;DR: MNP quantification provides biological insights for candidate AMD therapies and the number of infiltrating MNP cells does not correlate with the amount of laser-induced CNV area.
7
•Journal Article
A comparison of the effects of subretinal injection of scAAV2-CMV-GFP on retinal structure, visual function, and GFP expression by two injectors
Hui Li,Stephen Poor,Chad E Bigelow,Vivian Choi,Shawn Hanks,Joanna Vrouvlianis,Michael Maker,Steve Louie,Sha-Mei Liao,Bruce D Jaffee +9 more
1
AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice.
Vivian Choi,Chad E Bigelow,Terri L. McGee,Akshata N Gujar,Hui Li,Shawn Hanks,Joanna Vrouvlianis,Michael Maker,Barrett Leehy,Yiqin Zhang,Jorge Aranda,George Bounoutas,John Demirs,Junzheng Yang,Richard Ornberg,Yu Wang,Wendy Martin,Kelly R Stout,Gregory Argentieri,Paul A. Grosenstein,Danielle Diaz,Oliver C. Turner,Bruce D Jaffee,Thaddeus P. Dryja +23 more
TL;DR: Subretinal injection of scAAV8-p RLBP1-hRLBP1 in Rlbp1 nullizygous mice improved the rate of dark adaptation based on scotopic (rod-plus-cone) and photopic (cone) electroretinograms (ERGs).
Non-invasive molecular tracking method that measures ocular drug distribution in non-human primates
Guillaume Normand,Michael Maker,Jan Penraat,Kellyann Kovach,Kellyann Kovach,Joy Ghosh,Cynthia L. Grosskreutz,Sudeep Chandra +7 more
- 08 Jan 2020
TL;DR: Developing in cynomolgus monkeys a non-invasive fluorescence imaging technology that enables tracking of IVT-dosed drugs and could be easily translated into humans is presented, demonstrating the power of the technology for ocular pharmacokinetics.